Advertisement

Current Breast Cancer Reports

, Volume 10, Issue 2, pp 98–109 | Cite as

Individualizing Local-Regional Therapy of Breast Cancer in the Elderly

  • Apoorve Nayyar
  • Trevor A. Jolly
  • Ellen T. Jones
  • Kandace P. McGuire
  • Hyman B. Muss
  • Kristalyn K. GallagherEmail author
Local-Regional Evaluation and Therapy (DM Euhus, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Local-Regional Evaluation and Therapy

Abstract

Purpose of Review

The treatment of breast cancer in the elderly population requires a tailored approach. We summarize the current best evidence for personalized local-regional therapy in breast cancer patients older than 70.

Recent Findings

Breast cancer treatment in older adults incorporates the use of geriatric assessment tools to best evaluate functional status and treatment tolerability while accounting for the biologic profile of the disease. Surgical resection of the primary tumor with lymph node evaluation remains the cornerstone of local-regional control. Recent clinical trials demonstrate that surgery and radiation therapy may, however, be safely omitted in selected patients who are eligible for primary endocrine therapy. In patients with high-risk node-positive disease, DFS can be improved by systemic chemotherapy, but potential toxicity should be carefully considered in this population.

Summary

Patient-specific evaluation of the risks of both under- and over-treatment of breast cancer in the older adult is essential for delivering optimal care in this population.

Keywords

Breast cancer Local-regional management Geriatric assessment Elderly 

Notes

Compliance with Ethical Standards

Conflict of Interest

The authors declare that they have no competing interests.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers with particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Ferlay J, Shin H-R, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127(12):2893–917.  https://doi.org/10.1002/ijc.25516.CrossRefPubMedGoogle Scholar
  2. 2.
    Lewis DR, Chen H-S, Cockburn MG, Wu XC, Stroup AM, Midthune DN, et al. Early estimates of SEER cancer incidence, 2014. Cancer. 2017;123(13):2524–34.  https://doi.org/10.1002/cncr.30630.
  3. 3.
    Karuturi M, VanderWalde N, Muss H. Approach and management of breast cancer in the elderly. Clin Geriatr Med. 2016;32(1):133–53.  https://doi.org/10.1016/j.cger.2015.08.011.CrossRefPubMedGoogle Scholar
  4. 4.
    Murthy VH, Krumholz HM, Gross CP. Participation in cancer clinical trials: race-, sex-, and age-based disparities. JAMA. 2004;291(22):2720–6.CrossRefPubMedGoogle Scholar
  5. 5.
    • Hurria A, Levit LA, Dale W, Mohile SG, Muss HB, Fehrenbacher L, et al. Improving the evidence base for treating older adults with cancer: American Society of Clinical Oncology statement. J Clin Oncol. 2015;33(32):3826–33.  https://doi.org/10.1200/JCO.2015.63.0319. ASCO recommendations for improving representation of older adults in clinical trails and implementing evidence based guidelines in this population.
  6. 6.
    Malik MK, Tartter PI, Belfer R. Undertreated breast cancer in the elderly. Journal of Cancer Epidemiology. 2013;2013:893104.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Mehnert A, Koch U. Psychological comorbidity and health-related quality of life and its association with awareness, utilization, and need for psychosocial support in a cancer register-based sample of long-term breast cancer survivors. J Psychosom Res. 2008;64(4):383–91.  https://doi.org/10.1016/j.jpsychores.2007.12.005.CrossRefPubMedGoogle Scholar
  8. 8.
    DeMichele A, Putt M, Zhang Y, Glick JH, Norman S. Older age predicts a decline in adjuvant chemotherapy recommendations for patients with breast carcinoma: evidence from a tertiary care cohort of chemotherapy-eligible patients. Cancer. 2003;97(9):2150–9.  https://doi.org/10.1002/cncr.11338.CrossRefPubMedGoogle Scholar
  9. 9.
    Wanebo HJ, Cole B, Chung M, et al. Is surgical management compromised in elderly patients with breast cancer? Ann Surg. 1997;225(5):579–86. discussion586–9CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Gajdos C, Tartter PI, Bleiweiss IJ, Lopchinsky RA, Bernstein JL. The consequence of undertreating breast cancer in the elderly. J Am Coll Surg. 2001;192(6):698–707.CrossRefPubMedGoogle Scholar
  11. 11.
    Smith BD, Jiang J, McLaughlin SS, et al. Improvement in breast cancer outcomes over time: are older women missing out? J Clin Oncol. 2011;29(35):4647–53.  https://doi.org/10.1200/JCO.2011.35.8408.CrossRefPubMedGoogle Scholar
  12. 12.
    Jørgensen TL, Hallas J, Friis S, Herrstedt J. Comorbidity in elderly cancer patients in relation to overall and cancer-specific mortality. Br J Cancer. 2012;106(7):1353–60.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Land LH, Dalton SO, Jensen M-B, Ewertz M. Impact of comorbidity on mortality: a cohort study of 62,591 Danish women diagnosed with early breast cancer, 1990-2008. Breast Cancer Res Treat. 2012;131(3):1013–20.  https://doi.org/10.1007/s10549-011-1819-1.CrossRefPubMedGoogle Scholar
  14. 14.
    Berglund A, Wigertz A, Adolfsson J, Ahlgren J, Fornander T, Wärnberg F, et al. Impact of comorbidity on management and mortality in women diagnosed with breast cancer. Breast Cancer Res Treat. 2012;135(1):281–9.  https://doi.org/10.1007/s10549-012-2176-4.
  15. 15.
    Giordano SH, Duan Z, Kuo Y-F, Hortobagyi GN, Goodwin JS. Use and outcomes of adjuvant chemotherapy in older women with breast cancer. J Clin Oncol. 2006;24(18):2750–6.  https://doi.org/10.1200/JCO.2005.02.3028.CrossRefPubMedGoogle Scholar
  16. 16.
    Freyer G, Geay J-F, Touzet S, Provencal J, Weber B, Jacquin JP, et al. Comprehensive geriatric assessment predicts tolerance to chemotherapy and survival in elderly patients with advanced ovarian carcinoma: a GINECO study. Ann Oncol. 2005;16(11):1795–800.  https://doi.org/10.1093/annonc/mdi368.
  17. 17.
    Inouye SK, Peduzzi PN, Robison JT, Hughes JS, Horwitz RI, Concato J. Importance of functional measures in predicting mortality among older hospitalized patients. JAMA. 1998;279(15):1187–93.CrossRefPubMedGoogle Scholar
  18. 18.
    Klepin H, Mohile S, Hurria A. Geriatric assessment in older patients with breast cancer. J Natl Compr Cancer Netw. 2009;7(2):226–36.CrossRefGoogle Scholar
  19. 19.
    • Muss HB, Berry DA, Cirrincione CT, et al. Standard chemotherapy versus capcitabine for older women with early stage breast cancer: an update of CALGB/CTSU/alliance 49907. J Clin Oncol. 2015;33(15_suppl):1022–2.  https://doi.org/10.1200/jco.2015.33.15_suppl.1022. Clinical trial that demonstrates significant benefit of standard polychemotherapy over single-agent oral chemotherapy.
  20. 20.
    Besic N, Besic H, Peric B, Pilko G, Petric R, Zmuc J, et al. Surgical treatment of breast cancer in patients aged 80 years or older—how much is enough? BMC Cancer. 2014;14:700.Google Scholar
  21. 21.
    Perez EA, Suman VJ, Davidson NE, Sledge GW, Kaufman PA, Hudis CA, et al. Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the north central cancer treatment group N9831 adjuvant breast cancer trial. J Clin Oncol. 2008;26(8):1231–8.  https://doi.org/10.1200/JCO.2007.13.5467.
  22. 22.
    Yancik R, Wesley MN, Ries LA, Havlik RJ, Edwards BK, Yates JW. Effect of age and comorbidity in postmenopausal breast cancer patients aged 55 years and older. JAMA. 2001;285(7):885–92.CrossRefPubMedGoogle Scholar
  23. 23.
    Yates JW, Chalmer B, McKegney FP. Evaluation of patients with advanced cancer using the Karnofsky performance status. Cancer. 1980;45(8):2220–4.CrossRefPubMedGoogle Scholar
  24. 24.
    •• Jolly TA, Deal AM, Nyrop KA, Williams GR, Pergolotti M, Wood WA, et al. Geriatric assessment-identified deficits in older cancer patients with normal performance status. Oncologist. 2015;20(4):379–85. Landmark paper addressing the deficits in existing geriatric assessment tools and provides a brief geriatric assessment tool which can be implemented in routine practice Google Scholar
  25. 25.
    Folstein MF, Folstein SE, McHugh PR. “Mini-mental state.” A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12(3):189–198.Google Scholar
  26. 26.
    Katzman R, Brown T, Fuld P, Peck A, Schechter R, Schimmel H. Validation of a short orientation-memory-concentration test of cognitive impairment. Am J Psychiatry. 1983;140(6):734–9.  https://doi.org/10.1176/ajp.140.6.734.CrossRefPubMedGoogle Scholar
  27. 27.
    Pfeiffer E. A short portable mental status questionnaire for the assessment of organic brain deficit in elderly patients. J Am Geriatr Soc. 1975;23(10):433–41.CrossRefPubMedGoogle Scholar
  28. 28.
    Jacobsen PB, Donovan KA, Trask PC, Fleishman SB, Zabora J, Baker F, et al. Screening for psychologic distress in ambulatory cancer patients. Cancer. 2005;103(7):1494–502.  https://doi.org/10.1002/cncr.20940.
  29. 29.
    Sherbourne CD, Stewart AL. The MOS social support survey. Soc Sci Med. 1991;32(6):705–14.CrossRefPubMedGoogle Scholar
  30. 30.
    Robb C, Haley WE, Balducci L, Extermann M, Perkins EA, Small BJ, et al. Impact of breast cancer survivorship on quality of life in older women. Crit Rev Oncol Hematol. 2007;62(1):84–91.  https://doi.org/10.1016/j.critrevonc.2006.11.003.
  31. 31.
    Kreling B, Figueiredo MI, Sheppard VL, Mandelblatt JS. A qualitative study of factors affecting chemotherapy use in older women with breast cancer: barriers, promoters, and implications for intervention. Psychooncology. 2006;15(12):1065–76.  https://doi.org/10.1002/pon.1042.CrossRefPubMedGoogle Scholar
  32. 32.
    Smith BD, Gross CP, Smith GL, Galusha DH, Bekelman JE, Haffty BG. Effectiveness of radiation therapy for older women with early breast cancer. J Natl Cancer Inst. 2006;98(10):681–90.  https://doi.org/10.1093/jnci/djj186.CrossRefPubMedGoogle Scholar
  33. 33.
    Vaidya JS, Wenz F, Bulsara M, Tobias JS, Joseph DJ, Keshtgar M, et al. Risk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT-A randomised trial. Lancet. 2014;383(9917):603–13.  https://doi.org/10.1016/S0140-6736(13)61950-9.
  34. 34.
    Veronesi U, Orecchia R, Maisonneuve P, Viale G, Rotmensz N, Sangalli C, et al. Intraoperative radiotherapy versus external radiotherapy for early breast cancer (ELIOT): a randomised controlled equivalence trial. The Lancet Oncology. 2013;14(13):1269–77.  https://doi.org/10.1016/S1470-2045(13)70497-2.
  35. 35.
    Neumaier C, Elena S, Grit W, Yasser AM, Uta KT, Anke K, et al. TARGIT-E(lderly)—prospective phase II study of intraoperative radiotherapy (IORT) in elderly patients with small breast cancer. BMC Cancer. 2012;12:171.  https://doi.org/10.1186/1471-2407-12-171.
  36. 36.
    Fisher B, Bryant J, Dignam JJ, Wickerham DL, Mamounas EP, Fisher ER, et al. Tamoxifen, radiation therapy, or both for prevention of ipsilateral breast tumor recurrence after lumpectomy in women with invasive breast cancers of one centimeter or less. J Clin Oncol. 2002;20(20):4141–9.  https://doi.org/10.1200/JCO.2002.11.101.
  37. 37.
    Fyles AW, McCready DR, Manchul LA, et al. Tamoxifen with or without breast irradiation in women 50 years of age or older with early breast cancer. N Engl J Med. 2004;351(10):963–70.CrossRefPubMedGoogle Scholar
  38. 38.
    •• Hughes KS, Schnaper LA, Bellon JR, Cirrincione CT, Berry DA, McCormick B, et al. Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343. J Clin Oncol. 2013;31(19):2382–7.  https://doi.org/10.1200/JCO.2012.45.2615. Landmark clinical trial demonstrating equivalent outcomes in older patients receiving tamoxifen with or without radiation therapy.
  39. 39.
    Warren JL, Brown ML, Fay MP, Schussler N, Potosky AL, Riley GF. Costs of treatment for elderly women with early-stage breast cancer in fee-for-service settings. J Clin Oncol. 2002;20(1):307–16.  https://doi.org/10.1200/JCO.2002.20.1.307.CrossRefPubMedGoogle Scholar
  40. 40.
    DiMatteo MR. Social support and patient adherence to medical treatment: a meta-analysis. Health Psychol. 2004;23(2):207–18.CrossRefPubMedGoogle Scholar
  41. 41.
    Gennari R, Curigliano G, Rotmensz N, Robertson C, Colleoni M, Zurrida S, et al. Breast carcinoma in elderly women: features of disease presentation, choice of local and systemic treatments compared with younger postmenopasual patients. Cancer. 2004;101(6):1302–10.  https://doi.org/10.1002/cncr.20535.
  42. 42.
    Kaur P, Santillan AA, McGuire K, Turaga KK, Shamehdi C, Meade T, et al. The surgical treatment of breast cancer in the elderly: a single institution comparative review of 5235 patients with 1028 patients >/=70 years. Breast J. 2012;18(5):428–35.  https://doi.org/10.1111/j.1524-4741.2012.01272.x.
  43. 43.
    Eagle KA, Berger PB, Calkins H, Chaitman BR, Ewy GA, Fleischmann KE, et al. ACC/AHA guideline update for perioperative cardiovascular evaluation for noncardiac surgery—executive summary a report of the American College of Cardiology/American Heart Association task force on practice guidelines (committee to update the 1996 guidelines on perioperative cardiovascular evaluation for noncardiac surgery). Circulation. 2002;105(10):1257–67.Google Scholar
  44. 44.
    Oakley N, Dennison AR, Shorthouse AJ. A prospective audit of simple mastectomy under local anaesthesia. Eur J Surg Oncol (EJSO). 1996;22(2):134–6.CrossRefGoogle Scholar
  45. 45.
    Groeben H, Schafer B, Pavlakovic G, Silvanus M-T, Peters J. Lung function under high thoracic segmental epidural anesthesia with ropivacaine or bupivacaine in patients with severe obstructive pulmonary disease undergoing breast surgery. Anesthesiology. 2002;96(3):536–41.CrossRefPubMedGoogle Scholar
  46. 46.
    Fisher B, Jeong J-H, Anderson S, Bryant J, Fisher ER, Wolmark N. Twenty-five-year follow-up of a randomized trial comparing radical mastectomy, total mastectomy, and total mastectomy followed by irradiation. N Engl J Med. 2002;347(8):567–75.CrossRefPubMedGoogle Scholar
  47. 47.
    Fisher B, Anderson S, Bryant J, Margolese RG, Deutsch M, Fisher ER, et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med. 2002;347(16):1233–41.  https://doi.org/10.1056/NEJMoa022152.
  48. 48.
    Veronesi U, Cascinelli N, Mariani L, Greco M, Saccozzi R, Luini A, et al. Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med. 2002;347(16):1227–32.Google Scholar
  49. 49.
    Effects of radiotherapy and surgery in early breast cancer. An overview of the randomized trials. N Engl J Med 1995;333(22):1444–1455. doi: https://doi.org/10.1056/NEJM199511303332202
  50. 50.
    Pierga J-Y, Girre V, Laurence V, Asselain B, Diéras V, Jouve M, et al. Characteristics and outcome of 1755 operable breast cancers in women over 70 years of age. Breast. 2004;13(5):369–75.Google Scholar
  51. 51.
    Mogal HD, Clark C, Dodson R, Fino NF, Howard-McNatt M. Outcomes after mastectomy and lumpectomy in elderly patients with early-stage breast cancer. Ann Surg Oncol. 2017;24(1):100–7.CrossRefPubMedGoogle Scholar
  52. 52.
    Biganzoli L, Wildiers H, Oakman C, Marotti L, Loibl S, Kunkler I, et al. Management of elderly patients with breast cancer: updated recommendations of the International Society of Geriatric Oncology (SIOG) and European Society of Breast Cancer Specialists (EUSOMA). The Lancet Oncology. 2012;13(4):e148–60.  https://doi.org/10.1016/S1470-2045(11)70383-7.
  53. 53.
    Bazan JG, Bittoni MA, Fisher JL, White JR. Trends in mastectomy rates over time in elderly women with stage I, hormone-sensitive breast cancer: A SEER-based study. J Clin Oncol. 2016;34(15_suppl):1063–3.  https://doi.org/10.1200/JCO.2016.34.15_suppl.1063.
  54. 54.
    August DA, Wilkins E, Rea T. Breast reconstruction in older women. Surgery. 1994;115(6):663–8.PubMedGoogle Scholar
  55. 55.
    Girotto JA, Schreiber J, Nahabedian MY. Breast reconstruction in the elderly: preserving excellent quality of life. Ann Plast Surg. 2003;50(6):572–8.  https://doi.org/10.1097/01.SAP.0000069064.68579.19.CrossRefPubMedGoogle Scholar
  56. 56.
    Howard-McNatt M, Forsberg C, Levine EA, DeFranzo A, Marks M, David L. Breast cancer reconstruction in the elderly. Am Surg. 2011;77(12):1640–3.PubMedGoogle Scholar
  57. 57.
    • Reddy KG, Strassle PD, McGuire KP. Role of age, tumor grade, and radiation therapy on immediate postmastectomy breast reconstruction. Clin Breast Cancer. December 2017;  https://doi.org/10.1016/j.clbc.2017.11.021. Recent retrospective study demonstrating the low rates of post mastectomy breast reconstruction with advancing age.
  58. 58.
    Burnier P, Hudry D, See L-A, Duvernay A, Roche M, Loustalot C, et al. Patient age and breast resection weight affect immediate postmastectomy breast reconstruction in ductal carcinoma in situ. J Plast Reconstr Aesthet Surg. 2016;69(1):37–41.  https://doi.org/10.1016/j.bjps.2015.09.023.
  59. 59.
    Martelli G, Miceli R, Daidone MG, Vetrella G, Cerrotta AM, Piromalli D, et al. Axillary dissection versus no axillary dissection in elderly patients with breast cancer and no palpable axillary nodes: results after 15 years of follow-up. Ann Surg Oncol. 2011;18(1):125–33.Google Scholar
  60. 60.
    Randomized trial comparing axillary clearance versus no axillary clearance in older patients with breast cancer: first results of international breast cancer study group trial 10–93. J Clin Oncol. 2006;24(3):337–344. doi: https://doi.org/10.1200/JCO.2005.01.5784.
  61. 61.
    Martelli G, Miceli R, Daidone MG, Vetrella G, Cerrotta AM, Piromalli D, et al. Axillary dissection versus no axillary dissection in elderly patients with breast cancer and no palpable axillary nodes: results after 15 years of follow-up. Ann Surg Oncol. 2011;18(1):125–33.Google Scholar
  62. 62.
    Krag DN, Anderson SJ, Julian TB, Brown AM, Harlow SP, Costantino JP, et al. Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial. Lancet Oncol. 2010;11(10):927–33.Google Scholar
  63. 63.
    Hunt KK, Ballman KV, McCall LM, et al. Factors associated with local-regional recurrence following a negative sentinel node dissection: results of the ACOSOG Z0010 trial. Ann Surg. 2012;256(3):428–36.CrossRefPubMedPubMedCentralGoogle Scholar
  64. 64.
    •• Giuliano AE, Ballman KV, McCall L, Beitsch PD, Brennan MB, Kelemen PR, et al. Effect of axillary dissection vs no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis: the ACOSOG Z0011 (alliance) randomized clinical trial. JAMA. 2017;318(10):918–26.  https://doi.org/10.1001/jama.2017.11470. Landmark clinical trial demonstrating equivalent 10 year overall and disease free survival in early stage breast cancer patients receiving axillary lymph node dissection or sentinel lymph node dissection alone.
  65. 65.
    Veronesi U, Orecchia R, Zurrida S, Galimberti V, Luini A, Veronesi P, et al. Avoiding axillary dissection in breast cancer surgery: a randomized trial to assess the role of axillary radiotherapy. Ann Oncol. 2005;16(3):383–8.  https://doi.org/10.1093/annonc/mdi089.
  66. 66.
    Cote R, Giuliano AE, Hawes D, et al. ACOSOG Z0010: A multicenter prognostic study of sentinel node (SN) and bone marrow (BM) micrometastases in women with clinical T1/T2 N0 M0 breast cancer. J Clin Oncol. 2010;28(18_suppl):CRA504–4.  https://doi.org/10.1200/jco.2010.28.18_suppl.cra504.
  67. 67.
    Biganzoli L. Management of elderly patients with breast cancer: updated recommendations of the International Society of Geriatric Oncology (SIOG) and European Society of Breast Cancer Specialists (EUSOMA). Lancet Oncol. 13(4):e148–60.Google Scholar
  68. 68.
    Donker M, van Tienhoven G, Straver ME, Meijnen P, van de Velde CJH, Mansel RE, et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial. Lancet Oncol. 2014;15(12):1303–10.  https://doi.org/10.1016/S1470-2045(14)70460-7.
  69. 69.
    Ho A, Morrow M. The evolution of the Locoregional therapy of breast cancer. Oncologist. 2011;16(10):1367–79.CrossRefPubMedPubMedCentralGoogle Scholar
  70. 70.
    Forrest AP, Stewart HJ, Everington D, Prescott RJ, McArdle C, Harnett AN, et al. Randomised controlled trial of conservation therapy for breast cancer: 6-year analysis of the Scottish trial. Scottish Cancer Trials Breast Group Lancet. 1996;348(9029):708–13.Google Scholar
  71. 71.
    Winzer K-J, Sauerbrei W, Braun M, Liersch T, Dunst J, Guski H, et al. Radiation therapy and tamoxifen after breast-conserving surgery: updated results of a 2 x 2 randomised clinical trial in patients with low risk of recurrence. Eur J Cancer. 2010;46(1):95–101.  https://doi.org/10.1016/j.ejca.2009.10.007.
  72. 72.
    Fisher B, Anderson S, Bryant J, Margolese RG, Deutsch M, Fisher ER, et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med. 2002;347(16):1233–41.Google Scholar
  73. 73.
    Veronesi U, Luini A, Galimberti V, Zurrida S. Conservation approaches for the management of stage I/II carcinoma of the breast: Milan Cancer Institute trials. World J Surg. 1994;18(1):70–5.CrossRefPubMedGoogle Scholar
  74. 74.
    Blamey RW. Radiotherapy or tamoxifen after conserving surgery for breast cancers of excellent prognosis: British Association of Surgical Oncology (BASO) II trial. Eur J Cancer. 49(10):2294–302.Google Scholar
  75. 75.
    Martelli G. Elderly breast cancer patients treated by conservative surgery alone plus adjuvant tamoxifen. Cancer. 2008;112(3):481–8.CrossRefPubMedGoogle Scholar
  76. 76.
    •• Kunkler IH, Williams LJ, Jack WJL, Cameron DA, Dixon JM. Breast-conserving surgery with or without irradiation in women aged 65 years or older with early breast cancer (PRIME II): a randomised controlled trial. Lancet Oncol. 2015;16(3):266–73.  https://doi.org/10.1016/S1470-2045(14)71221-5. Landmark clinical trial providing evidence for safety of omitting radiation therapy in carefully selected older breast cancer patients. CrossRefPubMedGoogle Scholar
  77. 77.
    Hind D, Wyld L, Beverley CB, Reed MW. Surgery versus primary endocrine therapy for operable primary breast cancer in elderly women (70 years plus). Cochrane Database Syst Rev. 2006;1:CD004272.  https://doi.org/10.1002/14651858.CD004272.pub2.CrossRefGoogle Scholar
  78. 78.
    Mustacchi G, Scanni A, Capasso I, Farris A, Pluchinotta A, Isola G. Update of the phase III trial “GRETA” of surgery and tamoxifen versus tamoxifen alone for early breast cancer in elderly women. Future Oncol. 2015;11(6):933–41.  https://doi.org/10.2217/fon.14.266.CrossRefPubMedGoogle Scholar
  79. 79.
    Colleoni M, Giobbie-Hurder A, Regan MM, Thürlimann B, Mouridsen H, Mauriac L, et al. Analyses adjusting for selective crossover show improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG 1-98 study. J Clin Oncol. 2011;29(9):1117–24.  https://doi.org/10.1200/JCO.2010.31.6455.
  80. 80.
    Forbes JF, Cuzick J, Buzdar A, Howell A, Tobias JS, Baum M. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol. 2008;9(1):45–53.  https://doi.org/10.1016/S1470-2045(07)70385-6.CrossRefPubMedGoogle Scholar
  81. 81.
    Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials. Lancet. 2015;386(10001):1353–1361. doi: https://doi.org/10.1016/S0140-6736(15)60908-4.
  82. 82.
    Ravdin PM, Siminoff LA, Davis GJ, Mercer MB, Hewlett J, Gerson N, et al. Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J Clin Oncol. 2001;19(4):980–91.  https://doi.org/10.1200/JCO.2001.19.4.980.
  83. 83.
    van de Vijver MJ, He YD, van 't Veer LJ, Dai H, Hart AAM, Voskuil DW, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med. 2002;347(25):1999–2009.  https://doi.org/10.1056/NEJMoa021967.
  84. 84.
    Fan C, Oh DS, Wessels L, Weigelt B, Nuyten DSA, Nobel AB, et al. Concordance among gene-expression–based predictors for breast cancer. N Engl J Med. 2006;355(6):560–9.  https://doi.org/10.1056/NEJMoa052933.
  85. 85.
    Cress RD, Chen YS, Morris CR, Chew H, Kizer KW. Underutilization of gene expression profiling for early-stage breast cancer in California. Cancer Causes Control. 2016;27(6):721–7.  https://doi.org/10.1007/s10552-016-0743-4.CrossRefPubMedPubMedCentralGoogle Scholar
  86. 86.
    • Petkov VI, Miller DP, Howlader N, et al. Breast-cancer-specific mortality in patients treated based on the 21-gene assay: a SEER population-based study. Npj Breast Cancer. 2016;2(1):e0128345.  https://doi.org/10.1038/npjbcancer.2016.17. Recent retrospective database study demonstrating the role of 21-gene Recurrence Score in predicting the benefit of chemotherapy. CrossRefGoogle Scholar
  87. 87.
    Elkin EB, Hurria A, Mitra N, Schrag D, Panageas KS. Adjuvant chemotherapy and survival in older women with hormone receptor-negative breast cancer: assessing outcome in a population-based, observational cohort. J Clin Oncol. 2006;24(18):2757–64.  https://doi.org/10.1200/JCO.2005.03.6053.CrossRefPubMedGoogle Scholar
  88. 88.
    Muss HB, Berry DA, Cirrincione CT, Theodoulou M, Mauer AM, Kornblith AB, et al. Adjuvant chemotherapy in older women with early-stage breast cancer. N Engl J Med. 2009;360(20):2055–65.  https://doi.org/10.1056/NEJMoa0810266.
  89. 89.
    Minckwitz v G, Conrad B, Reimer T, et al. A randomized phase 2 study comparing EC or CMF versus nab-paclitaxel plus capecitabine as adjuvant chemotherapy for nonfrail elderly patients with moderate to high-risk early breast cancer (ICE II-GBG 52). Cancer. 2015;121(20):3639–48.  https://doi.org/10.1002/cncr.29506. CrossRefGoogle Scholar
  90. 90.
    Du XL, Osborne C, Goodwin JS. Population-based assessment of hospitalizations for toxicity from chemotherapy in older women with breast cancer. J Clin Oncol. 2002;20(24):4636–42.  https://doi.org/10.1200/JCO.2002.05.088.CrossRefPubMedPubMedCentralGoogle Scholar
  91. 91.
    Kornblith AB, Lan L, Archer L, Partridge A, Kimmick G, Hudis C, et al. Quality of life of older patients with early-stage breast cancer receiving adjuvant chemotherapy: a companion study to cancer and leukemia group B 49907. J Clin Oncol. 2011;29(8):1022–8.  https://doi.org/10.1200/JCO.2010.29.9859.
  92. 92.
    •• Cameron D, Piccart-Gebhart MJ, Gelber RD, et al. 11 years’ follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial. Lancet. 2017;389(10075):1195–205.  https://doi.org/10.1016/S0140-6736(16)32616-2. Landmark clinical trial demonstrating the benefit of 1-year of trastuzumab in HER2-positive breast cancer patients. CrossRefPubMedPubMedCentralGoogle Scholar
  93. 93.
    Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005;353(16):1659–72.  https://doi.org/10.1056/NEJMoa052306.
  94. 94.
    Tan-Chiu E, Yothers G, Romond E, Geyer CE Jr, Ewer M, Keefe D, et al. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol. 2005;23(31):7811–9.  https://doi.org/10.1200/JCO.2005.02.4091.

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • Apoorve Nayyar
    • 1
    • 2
  • Trevor A. Jolly
    • 1
    • 3
  • Ellen T. Jones
    • 1
    • 4
  • Kandace P. McGuire
    • 5
    • 6
  • Hyman B. Muss
    • 1
    • 3
  • Kristalyn K. Gallagher
    • 1
    • 2
    Email author
  1. 1.UNC Lineberger Comprehensive Cancer CenterChapel HillUSA
  2. 2.Department of Surgery, Division of Surgical OncologyThe University of North Carolina at Chapel HillChapel HillUSA
  3. 3.Hematology and Oncology DivisionUNC School of MedicineChapel HillUSA
  4. 4.Department of Radiation OncologyThe University of North Carolina at Chapel HillChapel HillUSA
  5. 5.Department of SurgeryVCU School of MedicineRichmondUSA
  6. 6.Massey Cancer CenterVirginia Commonwealth UniversityRichmondUSA

Personalised recommendations